- Home
- VTLE vs RCUS Comparison
VTLE vs RCUS Comparison
Compare VTLE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- RCUS
- Stock Information
- Founded
- VTLE 2006
- RCUS 2015
- Country
- VTLE United States
- RCUS United States
- Employees
- VTLE N/A
- RCUS N/A
- Industry
- VTLE
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- RCUS Health Care
- Exchange
- VTLE Nasdaq
- RCUS Nasdaq
- Market Cap
- VTLE 1.2B
- RCUS 1.4B
- IPO Year
- VTLE 2011
- RCUS 2018
- Fundamental
- Price
- VTLE $30.66
- RCUS $15.72
- Analyst Decision
- VTLE Hold
- RCUS Buy
- Analyst Count
- VTLE 13
- RCUS 12
- Target Price
- VTLE $47.91
- RCUS $34.50
- AVG Volume (30 Days)
- VTLE 849.1K
- RCUS 932.9K
- Earning Date
- VTLE 11-06-2024
- RCUS 11-06-2024
- Dividend Yield
- VTLE N/A
- RCUS N/A
- EPS Growth
- VTLE N/A
- RCUS N/A
- EPS
- VTLE 13.16
- RCUS N/A
- Revenue
- VTLE $1,862,465,000.00
- RCUS $263,000,000.00
- Revenue This Year
- VTLE $28.07
- RCUS $112.97
- Revenue Next Year
- VTLE $7.97
- RCUS N/A
- P/E Ratio
- VTLE $2.35
- RCUS N/A
- Revenue Growth
- VTLE 26.94
- RCUS 119.17
- 52 Week Low
- VTLE $25.85
- RCUS $13.50
- 52 Week High
- VTLE $58.30
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- VTLE 62.67
- RCUS 43.78
- Support Level
- VTLE $29.51
- RCUS $15.03
- Resistance Level
- VTLE $32.24
- RCUS $18.98
- Average True Range (ATR)
- VTLE 1.38
- RCUS 1.02
- MACD
- VTLE 0.50
- RCUS -0.04
- Stochastic Oscillator
- VTLE 86.72
- RCUS 20.07
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.